|
Alimera Sciences' tunnel vision is a real asset. The biopharmaceutical company specializes in prescription ophthalmic pharmaceuticals, particularly those aimed at treating ocular diseases affecting the retina. Alimera's most advanced product candidate, Iluvien, is an insert about the size of a grain of rice that slowly releases a drug to the back of the eye used in the treatment of diabetic macular edema (DME); DME, a retinal disease affecting diabetics, can lead to severe vision loss and blindness. Iluvien is effective for up to 36 months and may also have the potential to affect other ophthalmic diseases, such as retinal vein occlusion (RVO). Alimera Sciences is looking to go public through an $80 million IPO.
|
| | | Contact Information | |
Address: |
6120 Windward Pkwy., Ste. 290
Alpharetta, GA 30005
| | Phone: | 678-990-5740 | | Fax: | 678-990-5744 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 0.00 M | | Employees (2008): | 21 | | Employee Growth (1 yr): | 0.00% |
|
|
Key People
| | • |
Chairman:
Philip R. Tracy
| | • |
President, CEO, and Director:
C. Daniel (Dan) Myers
| | • |
CFO:
Richard S. (Rick) Eiswirth Jr.
|
|
|
